Creative Financial Designs Inc. ADV Cuts Stock Position in Kenvue Inc. $KVUE

Creative Financial Designs Inc. ADV lessened its holdings in Kenvue Inc. (NYSE:KVUE) by 92.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,145 shares of the company’s stock after selling 39,581 shares during the period. Creative Financial Designs Inc. ADV’s holdings in Kenvue were worth $54,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of KVUE. Cornerstone Planning Group LLC increased its stake in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares in the last quarter. Physician Wealth Advisors Inc. increased its stake in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in Kenvue in the 4th quarter worth $26,000. Golden State Wealth Management LLC increased its stake in Kenvue by 150.1% in the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock worth $32,000 after buying an additional 1,190 shares in the last quarter. Finally, SBI Securities Co. Ltd. increased its stake in Kenvue by 82.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after buying an additional 1,027 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.1%

Shares of KVUE stock opened at $17.55 on Monday. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $24.00. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. The stock’s 50-day moving average price is $17.40 and its 200-day moving average price is $17.43. The stock has a market capitalization of $33.69 billion, a price-to-earnings ratio of 20.64, a price-to-earnings-growth ratio of 1.33 and a beta of 0.55.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. During the same period in the previous year, the firm posted $0.24 earnings per share. The business’s revenue was up 4.5% compared to the same quarter last year. Equities research analysts predict that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th will be issued a $0.2075 dividend. The ex-dividend date of this dividend is Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is presently 97.65%.

Insider Activity at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.59% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on KVUE. Barclays cut their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. Citigroup cut their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 8th. Finally, UBS Group reduced their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat, Kenvue has an average rating of “Hold” and a consensus price target of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.